Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update.

Cancers (Basel) · 2022 · PMC9454768 · PMID 36077740

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The recently published phase III CheckMate 459 trial was the first study to evaluate nivolumab compared with sorafenib in the first-line setting; though nivolumab was well tolerated and trended towards improved median OS, this finding did not reach statistical significance [ 52 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.